In a significant move to enhance the safety and efficacy of medicines, India has unveiled the 10th edition of its official drug standards, the Indian Pharmacopoeia 2026 (IP-2026). Released by Union Health Minister J.P. Nadda on January 2, 2026, this edition introduces 121 new monographs, bringing the total to 3,340. (, Japanese Pharmacopoeia (JP), and United States Pharmacopoeia (USP).
India's commitment to enhancing drug quality is further demonstrated by its progress in pharmacovigilance. The country has risen from 123rd to 8th globally in contributions to the World Health Organization's pharmacovigilance database by 2025.
The release of IP-2026 marks a significant milestone in India's ongoing efforts to strengthen the quality, safety, and efficacy of medicines, reinforcing its position as a leader in global pharmaceutical manufacturing and regulation.